Skip to content

Study · Not a test of the peptide alone · 2023

5 results

Doxorubicin-Loaded Liposome with the Function of "Killing Two Birds with One Stone" against Glioma.

Cen J, Dai X, Zhao H, Li X, Hu X, Wu J, Duan S

ACS applied materials & interfaces2 Oct 2023Cited by 17 (Europe PMC)

PMID37782688 (opens in a new tab)DOI10.1021/acsami.3c10364 (opens in a new tab)PepBankPUB-37782688
Publisher pagePubMedAsk about this study
Jump to 5 results

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study5

No result from this study comes from a test of the peptide.

Studies that did not test the peptide alone5

In this study, Elamipretide (SS-31) was a lab tool or a carrier, part of a mix, or the subject of a lab method. These results are not evidence about taking Elamipretide (SS-31).

  1. 01AnimalNot a test of Elamipretide (SS-31) aloneAnimal study (in vivo)Efficacy outcome

    In nude mice with in situ glioma, the SS31-modified doxorubicin liposomes showed a good therapeutic effect.

    In plain wordsIn mice with brain tumours, a liposome with doxorubicin and SS31 had a good treatment effect.

    Peptide
    Elamipretide (SS-31)
    Outcome
    Direction not reportedTherapeutic effect on in situ glioma
    Study

    mousen: not reported in source

    Nude mice with in situ glioma
    Outcome group
    Tumor growth · Cancer

    Source sentences

    Summary
    In addition, the liposomes showed a good therapeutic effect on nude mice with glioma in situ with no obvious toxicity and side effects.
    1 context sentence
    Summary · context
    In this study, a new liposomal delivery system, LS-DOX, was prepared by modifying DOX-loaded liposomes with SS31 for the treatment of in situ glioma.

    In this study, Elamipretide (SS-31) was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Elamipretide (SS-31).

  2. 02AnimalNot a test of Elamipretide (SS-31) aloneAnimal study (in vivo)Safety outcome

    In nude mice with in situ glioma, the SS31-modified doxorubicin liposomes caused no obvious toxicity or side effects.

    In plain wordsIn mice with brain tumours, the SS31 and doxorubicin liposome caused no obvious toxicity or side effects.

    Peptide
    Elamipretide (SS-31)
    Outcome
    No significant changeToxicity and side effects
    Study

    mousen: not reported in source

    Nude mice with in situ glioma
    Outcome group
    Adverse events · Cancer

    Source sentences

    Summary
    In addition, the liposomes showed a good therapeutic effect on nude mice with glioma in situ with no obvious toxicity and side effects.
    1 context sentence
    Summary · context
    In this study, a new liposomal delivery system, LS-DOX, was prepared by modifying DOX-loaded liposomes with SS31 for the treatment of in situ glioma.

    In this study, Elamipretide (SS-31) was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Elamipretide (SS-31).

  3. 03AnimalNot a test of Elamipretide (SS-31) aloneAnimal study (in vivo)Pharmacokinetics

    The SS31-modified doxorubicin liposomes crossed the blood-brain barrier and targeted gliomas.

    In plain wordsIn the study, the liposomes crossed the blood-brain barrier and reached brain tumours.

    Peptide
    Elamipretide (SS-31)
    Outcome
    Not applicableBlood-brain barrier crossing and glioma targeting
    Study

    n: not reported in source

    Outcome group
    Pharmacokinetics · Cancer

    Source sentences

    Summary
    Experimental results showed that the liposomes could effectively cross the BBB and target gliomas
    1 context sentence
    Summary · context
    In this study, a new liposomal delivery system, LS-DOX, was prepared by modifying DOX-loaded liposomes with SS31 for the treatment of in situ glioma.

    In this study, Elamipretide (SS-31) was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Elamipretide (SS-31).

  4. 04LabNot a test of Elamipretide (SS-31) aloneIn vitro (cells)Mechanism

    Mitochondria-targeting by SS31 enhanced cell uptake of the doxorubicin liposomes.

    In plain wordsIn cells, SS31 on the liposome increased how much of the liposome the cells took up.

    Peptide
    Elamipretide (SS-31)
    Outcome
    IncreaseCell uptake
    Study

    n: not reported in source

    Outcome group
    Receptor activity and mechanism · Cancer

    Source sentences

    Summary
    mitochondria-targeting of SS31 enhances cell uptake.
    1 context sentence
    Summary · context
    In this study, a new liposomal delivery system, LS-DOX, was prepared by modifying DOX-loaded liposomes with SS31 for the treatment of in situ glioma.

    In this study, Elamipretide (SS-31) was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Elamipretide (SS-31).

  5. 05LabNot a test of Elamipretide (SS-31) aloneIn vitro (cell-free)Other

    The SS31-modified doxorubicin liposomes showed a high drug encapsulation rate, high drug-loading capacity, satisfactory biocompatibility, high glioma accumulation and good stability in vitro.

    In plain wordsIn lab tests, the liposomes held a lot of drug, were compatible with biological material and stayed stable.

    Peptide
    Elamipretide (SS-31)
    Outcome
    Not applicableEncapsulation, drug loading, biocompatibility and stability
    Study

    n: not reported in source

    Outcome group
    Formulation, delivery and stability · Pharmacology

    Source sentences

    Summary
    The liposomes demonstrated a high drug encapsulation rate and drug-loading capacity, satisfactory biocompatibility, high glioma accumulation ability, and good stability in vitro.
    1 context sentence
    Summary · context
    In this study, a new liposomal delivery system, LS-DOX, was prepared by modifying DOX-loaded liposomes with SS31 for the treatment of in situ glioma.

    In this study, Elamipretide (SS-31) was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Elamipretide (SS-31).

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

  1. Version 2Current

    10 Oct 2026, 08:19 UTC

    Study results updated

  2. Version 1

    9 Oct 2026, 02:47 UTC

    First added · source update from Europe PMC

Subjects

Terms as the source lists them.

Publication types

PepBank is a research reference. Talk to a doctor before you use any peptide.